Payment overview · 2025
General Payments
$306.33
11 reported records · 6 companies
Healthcare provider profile · identity verified
Meghan Bonds, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENSBORO, AL · NPI 1477089217
Verified facts
What the public records show
CMS Open Payments records show Meghan Bonds, MD received $306.33 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.94 | 40.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $86.89 | 28.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.09 | 9.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.89 | 9.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.84 | 6.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.68 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.33 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.94 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $86.89 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 163 |
| Gabapentin | Gabapentin | 363 | 91 |
| Losartan Potassium | Losartan Potassium | 301 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 201 | 100 |
| Metformin Hcl | Metformin Hcl | 199 | 61 |
| Omeprazole | Omeprazole | 173 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 46 |
| Furosemide | Furosemide | 165 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 45 |
| Meloxicam | Meloxicam | 147 | 49 |
| Potassium Chloride | Potassium Chloride | 147 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 145 | 52 |
| Simvastatin | Simvastatin | 136 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 41 |
| Carvedilol | Carvedilol | 117 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 40 |
| Lisinopril | Lisinopril | 115 | 39 |
| Farxiga | Dapagliflozin Propanediol | 110 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 50 |
| Eliquis | Apixaban | 99 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 28 |
| Ozempic | Semaglutide | 79 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 24 |
| Famotidine | Famotidine | 69 | 29 |
| Donepezil Hcl | Donepezil Hcl | 65 | 16 |
| Ibuprofen | Ibuprofen | 64 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 20 |
| Pregabalin | Pregabalin | 61 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 21 |
| Clonidine Hcl | Clonidine Hcl | 57 | 16 |
| Spironolactone | Spironolactone | 57 | 21 |
| Montelukast Sodium | Montelukast Sodium | 53 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Tramadol Hcl | Tramadol Hcl | 49 | 18 |
| Celecoxib | Celecoxib | 47 | 12 |
| Prednisone | Prednisone | 47 | 41 |
| Atenolol | Atenolol | 46 | 12 |
| Jardiance | Empagliflozin | 45 | 15 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 43 | 16 |
| Chlorthalidone | Chlorthalidone | 42 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 17 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 22 |
| Nystatin | Nystatin | 36 | 19 |
| Sertraline Hcl | Sertraline Hcl | 34 | 15 |
| Metformin Hcl Er | Metformin Hcl | 33 | 15 |
| Finasteride | Finasteride | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | 13 |
| Ezetimibe | Ezetimibe | 28 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | 14 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 12 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 20 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Folic Acid | Folic Acid | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.33 · 11 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, Flector, LEQVIO, Licart, Ozempic, Tirosint, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error